Pane wikiwiki
Explore how unified, ready-to-use immunopeptidomics sample preparation kits reshape customized peptide design specifications, raise quality benchmarks for SIL AQUA quantitative peptide reagents, restructure routine liquid chromatography-mass spectrometry operational workflows, streamline laboratory pretreatment procedures, cut manual operation errors, and unify detection standards for tumor immunopeptide mass spectrometry analysis.
He aha ke ʻano o kā Thermo Fisher's New Immunopeptidomics Kit no nā Kaʻina Hana Peptide Maʻamau

Ua hoʻololi ʻia ka immunopeptidomics e pili ana i ka nui spectrometry mai kahi mea hana ʻike hoʻonaʻauao kūikawā i kahi kia bioanalytical koʻikoʻi no ka biopharmaceutical R.&ʻO D. Mai ka loaʻa ʻana o ka maʻi kanulau neoantigen a me ka loaʻa ʻana o T-cell (TCR-T) ka ʻike maka i ka autoimmune target profiling, ninau pololei i ke kanaka leukocyte antigen (HLA)-Hāʻawi nā peptides i hoʻopaʻa ʻia i ka hōʻike hōʻike antigen. Eia naʻe, mōʻaukala, ʻokoʻa i ka hoʻomaʻemaʻe immunoaffinity (IP), hoʻokaʻawale peptide micro-scale, a me ka hoʻomaʻemaʻe laʻana lima i kaupalena ʻia i ka reproducibility ma waena o ka hale hana a me ka throughput assay.
ʻO ka hoʻolaha ʻana o nā pae hoʻomākaukau laʻana immunopeptidomics maʻamau-i hōʻike ʻia e Thermo Fisher Scientific's Pierce MHC Class I Antibody Coupling a me Immunoprecipitation Kit i hui pū ʻia me ka ultra-high-resolution Orbitrap Exploris a me Orbitrap Astral LC-MS/MS nā ʻōnaehana - e hōʻike ana i kahi mea nui i ka holomua o ka holo ʻana o ka hana analytical.. Ma ka hoʻohālikelike ʻana i ka antibody pan-MHC Class I (clone W6/32) ka hoʻopili ʻana i ka lei magnetic, haʻahaʻa-pH elution, a me ka hoʻomaʻemaʻe ʻana i ka C18, nā koena analytical downstream of variation (CV) ua hāʻule i lalo 15%.
Akā naʻe, ʻoiai e lilo ana ka laʻana prep spectrometry i lalo i mea maʻamau a hiki ke hana hou ʻia, puka mai kahi bottleneck analytical hou: nā kikoʻī peptide synthetic maʻamau upstream. Peptide
ʻoiai e lilo ana ka laʻana prep spectrometry i lalo i mea maʻamau a hiki ke hana hou ʻia, puka mai kahi bottleneck analytical hou: nā kikoʻī peptide synthetic maʻamau upstream.
Hoʻokiʻekiʻe nā kime maʻamau i nā manaʻolana no nā kūlana kuhikuhi synthetic, peptides hoʻopaʻa-manawa calibration, a me ka isotope kaumaha i hōʻailona ʻia (SIL) nā mana spike-in. Ke hoʻemi ʻia ka hoʻomākaukau ʻana o ka laʻana i lalo, synthetic peptide heterogeneity—e like me ka hoʻonui ʻana i ka isotopic, pololei ʻole ka ʻike peptide net, hoʻopilikia kūʻē i ka ion, a me ka hydrophobic aggregation—ʻo ia ke kumu kumu o ka hewa helu helu a me ka hōʻoia ʻana i ka pahuhopu hoʻopunipuni..
Ke nānā nei kēia loiloi pehea e hoʻololi ai nā kits immunopeptidomics standard i nā koi peptide maʻamau, loiloi i nā ʻāpana hoʻomalu maikaʻi koʻikoʻi e pono ai no ka hoʻohālikelike kit, a wehewehe i nā hoʻololi kūpono e pono ai nā mea hoʻolako peptide synthesis maʻamau e kākoʻo i ka noiʻi proteomic hou..
Hoʻomaʻamaʻa ʻana i ka laʻana o lalo o ka laʻana: ʻO ka Pierce MHC Kit Benchmark
E hoʻomaopopo i ke kumu e hoʻololi ai nā kikoʻī peptide upstream, Pono nā alakaʻi bioanalytical e kālele mua i ka kemika a me ka mechanics o nā pahu hoʻohaʻahaʻa maʻamau. Ma ka mōʻaukala, Ua hilinaʻi ka immunopeptidomics i nā kolamu Sepharose a i ʻole Protein A/G agarose i hoʻopaʻa ʻia e koi ana i ka crosslinking manual me ka dimethyl pimelimidate. (DMP), ka holoi ʻana i ka gravity he nui, a me ka hoʻomaʻemaʻe ʻana i nā mea hana lima. Hoʻokomo ʻia kēia mau protocol manual i nā ʻano like ʻole o ka holo a me ka pae kiʻekiʻe.
Hoʻoponopono nā pahu kalepa a hoʻohālikelike i kēia pipeline i kahi mana, ʻehā-pae micro-scale protocol optimized no ka haʻahaʻa-input cell lysates (10⁷ a hiki i 10⁸ pūnaewele) a i ʻole nā biopsies kiko:
Nā Immunopeptidomic Kūlana LC-MS/MS Pipeline
- ʻO ka hui ʻana o Antibody: Pan-specific anti-human HLA Class I antibody (clone W6/32) ua hui pono ia me ka Protein A/G magnetic agarose beads ma ka ratio paa (2.5 µg antibody no kēlā me kēia 1 µL slurry bead), ka hoʻopau ʻana i ka hana resin manual a me variabl
ʻĀpana 176-191 Peptide Haʻahaʻa-pH Elution: Hoʻokaʻawale ʻia nā paʻakikī HLA me ka hoʻohana ʻana i ka standardized 1% ʻakika trifluoroacetic (TFA) a hoʻoheheʻe paha 0.1 N ka ʻakika acetic, ka hookuu ana i paa 8- i nā peptide 11-mer ma ka ʻaoʻao o nā kaulahao kaumaha HLA a me ka beta-2 microglobulin (β2M).
r digiton).
- Haʻahaʻa-pH Elution: Hoʻokaʻawale ʻia nā paʻakikī HLA me ka hoʻohana ʻana i ka standardized 1% ʻakika trifluoroacetic (TFA) a hoʻoheheʻe paha 0.1 N ka ʻakika acetic, ka hookuu ana i paa 8- i nā peptide 11-mer ma ka ʻaoʻao o nā kaulahao kaumaha HLA a me ka beta-2 microglobulin (β2M).
- C18 Micro-Desalting & LC-MS/MS: Hoʻokaʻawale ʻia nā peptides mai nā protein kiʻekiʻe-molecular-weight me ka hoʻohana ʻana i nā ʻōlelo aʻoaʻo spin C18 a i ʻole nā tips microfluidic stage-tips., elued in 25% i 50% acetonitrile (ACN) e komo ana 0.1% TFA, maloʻo, hoʻohui hou ʻia i loko 0.1% ʻakika formic (FA), a kālailai ʻia ma o ka UHPLC hoʻololi hoʻonā kiʻekiʻe i hui pū ʻia me nā spectrometers nui..
Ki Takeaway: Hoʻopau nā pahu maʻamau i ka hoʻomākaukau kolamu IP manual, e ho'ēmi ana i ka laʻana like ʻole i lalo < 15% CV. No laila, nā hewa analytical i nā ho'āʻo PRM/DIA i manaʻo ʻia i kēia manawa ke kumu nui mai nā kūlana kuhikuhi peptide synthetic synthetic..
E like me ka kikoʻī ma ka noiʻi i paʻi ʻia ma ʻO ka PMC optiPRM i hoʻopaʻa ʻia i ka Immunopeptidomics Workflow (2024), ʻO ka hoʻoheheʻe ʻana i ka hāpana maʻamau a kit-standardized e hiki ai ke hoʻihoʻi hou ʻia i ka nānā ʻana i ka hopena like (PRM) a me ka loaʻa kūʻokoʻa ʻikepili (MAILA). Eia naʻe, ʻO ka loaʻa ʻana o ka nui piha pono e koi ʻia i nā kūlana peptide AQUA i kapa ʻia ʻo ia ka mea nona ka kūpaʻa kemika e like me ka pololei o ka spectrometer mass..
Nā hopena Ripple i luna: Hoʻololi hou i nā kikoʻī peptide maʻamau
ʻO ka hoʻohana ākea ʻana o nā kits immunopeptidomics maʻamau e hoʻololi i nā kikoʻī koi a me nā kikoʻī kino o nā peptides synthetic maʻamau ma waena o nā ʻāpana ʻehā.: solubility pae kaʻina, maʻemaʻe isotopic, hōʻoia maʻiʻo peptide net, a me ka hoomalu ana i ka ion.
(Ke koi nei no) ʻOkoʻa nui: ʻO ka ʻike peptide Net ma o ka Amino Acid Analysis (AAA) Kau-Ion & ʻO ka maʻemaʻe: Hoʻololi ʻole TFA & Papa 100 hana lumi maʻemaʻe
UPSTREAM PEPTIDE SPECIFICATION RIPPLE Downstream Standardization (Thermo Pierce MHC Kit) Haʻahaʻa-pH Elution (1% TFA) & C18 Micro-Cleanup Orbitrap LC-MS/MS Ka helu (PRM/HE) Nā Koina Peptide Kūʻokoʻa ma luna o ke kahawai Hydrophobic Sequence Handling: Anchor-aware synthesis no 8-11mers Isotopic Purity: > 99.0% ka hoʻohui ʻana i ka isotope kaumaha (13C/15N)
1. Navigating Hydrophobic Anchor Sequences and Aggregation
Hōʻike maoli nā molekala MHC Class I i nā peptides pōkole, maʻamau 8 i 11 nā amino acids i ka lōʻihi, ʻike ʻia e nā kumu hoʻolālā paʻa. Kūlana 2 (P2) a me ke kūlana C-terminal (P9/P10) e lilo i koena heleuma mua e ku ana i loko o nā ʻeke kikoʻī o ke kaulahao kaulahao kaumaha HLA. No nā allele maʻamau e like me HLA-A*02:01, ʻO kēia mau heleuma he ʻaneʻane wale nō ka hydrophobic aliphatic a i ʻole nā ʻakika amino aromatic: Leucine (Leu), Valine (ʻO Val), Isoleucine (Me), Methionine (Met), Phenylalanine (Ua haʻi aku ʻo Phe), a me Tyrosine (ʻO Tyr).
Ke hoʻohālikelike ʻia nā peptides maʻamau i kēia mau ligand HLA endogenous, ʻO kā lākou ʻano hydrophobic kiʻekiʻe e alakaʻi i ka insolubility wai nui a me ka adsorption wikiwiki ʻole i ka polypropylene microcentrifuge tubes a me nā hue LC autosampler..
- Insolubility i ka hoʻouka ʻana i nā Buffers: Nā pale hoʻoponopono LC-MS maʻamau (0.1% FA / 1% ACN) hiki ʻole ke hoʻoheheʻe pinepine i ka hydrophobic 9-mers, ke kumu o ka ua ma mua o ka hoʻokomo ʻana i ke kolamu.
- Na Pohō o ka Surface Adsorption: Ma ka picomolar a i ʻole ka femtomolar pae hoʻopaʻa ʻana i hoʻohana ʻia no nā pihi calibration LC-MS spike-in., Hoʻopili ʻia nā kaʻina peptide unpassivated ma nā paia pahu, hoʻololi i ka laina laina (R² < 0.95).
2. Isotopic Purity vs. Hoʻomanawanui Hapa Nui
No nā ho'āʻo immunopeptidomic i hoʻopaʻa ʻia me ka hoʻohana ʻana i ka nānā ʻana i ka Reaction Monitoring (SRM), Ka nānā ʻana i ka hoʻohālikelike ʻana (PRM), a i ʻole DIA me nā kūlana kūloko, Hoʻopili ʻia nā peptides synthetic me ka Stable Isotope Labeled (SIL) nā ʻakika amino. ʻO ka maʻamau, kaumaha Arg (13C6, 15N4; hoʻololi nuipaʻa +10 A) a i ʻole Lys kaumaha (13C6, 15N1; hoʻololi nuipaʻa +8 A) ua hookomoia ma ka C-terminus.
Ma nā mea hoʻonā kiʻekiʻe loa e like me ka Orbitrap Astral a i ʻole Orbitrap Eclipse e hana ana ma 120,000 i 240,000 mana hoʻoholo (m/z 200), kaohi ʻia ka ʻae ʻana i ka hewa nui i ≤ 5 ppm. ʻO ka hoʻonui ʻana i ka isotopic i ka wā o ka synthesis mua o ka amino acid e hana i ka "leakage isotope māmā" - nā ʻano peptide i hōʻailona ʻole ʻia i loko o ka maʻamau i kau inoa ʻia.. Inā hāʻule ka waiwai isotopic i lalo 99.0%, ʻo ke koena o ka hōʻailona kukui e uhi ʻia me nā ligands HLA haʻahaʻa haʻahaʻa, hana ana i nā hōʻailona helu kumu hoʻopunipuni.
3. Maʻiʻo Peptide Net: Ke neʻe nei ma waho o ka HPLC Optical Purity
ʻO ka manaʻo kuhihewa koʻikoʻi i ka kūʻai ʻana i ka peptide maʻamau e hoʻohālikelike ana i ka maʻemaʻe analytical RP-HPLC. (214 nm ka pakeneka wahi kiʻekiʻe) me ka manaʻo peptide piha.
Hōʻike wale ka maʻemaʻe RP-HPLC i ka nui o ka peptide se
Maʻiʻo Peptide Net (%) = Mass of Pure Peptide Src Peptides Laboratory Sequence/Total Lyophilized Powder Weight × 100
s, e like me ke koena o ka wai, counter-ions (trifluoroacetate a i ʻole acetate), a me na paakai paa. Hoʻonui maʻamau ke kaumaha o ka gravimetric i ka ʻike peptide maoli e 15% i 35%.
Maʻiʻo Peptide Net (%) = Ka nui o ke kaʻina peptide maʻemaʻe/ka pauka Lyophilized pauda kaumaha × 100
No nā kaila hana immunopeptidomic maʻamau e koi ana i ka helu piha (fmol/µL spike-ins), ka hilinaʻi ma ke kaumaha maloʻo nui hoʻolauna systematic qu
Hoʻohui ʻia ʻo Solid-Phase Peptide Synthesis (SPSS) hoʻohana i ka trifluoroacetic acid (TFA) no ka hoʻokaʻawale ʻana mai ka resin a me ka hoʻomaʻemaʻe hoʻohuli. Hiki i nā paʻakai trifluoroacetate ke kāohi i ka ionization electrospray (ESI) pono i ka wā Ka noiʻi 1 Mea Hoʻolako Peptides Nānā LC-MS. Eia kekahi, nā mea hoʻohaumia olaola hope (nā endotoxins, DNA bacteria koena, a i ʻole nā meheu o keratin/trypsin) i hoʻokomo ʻia i ka wā o ka peptide packaging hiki ke makapō i nā mea ʻike Orbitrap, e hana ana ma nā palena sub-femtomolar o ka ʻike.
Hiki i nā paʻakai trifluoroacetate ke kāohi i ka ionization electrospray (ESI) pono i ka wā o ka nānā ʻana o LC-MS. Eia kekahi, nā mea hoʻohaumia olaola hope (nā endotoxins, DNA bacteria koena, a i ʻole nā meheu o keratin/trypsin) i hoʻokomo ʻia i ka wā o ka peptide packaging hiki ke makapō i nā mea ʻike Orbitrap, e hana ana ma nā palena sub-femtomolar o ka ʻike.
Ka Mana Pono a me nā Koina Huli no nā Kūlana Kaumaha
E hoʻohālikelike i ka hana peptide maʻamau me nā pahu kiʻekiʻe-throughput, Pono nā mea kūʻai synthesis e hana hou i kā lākou Quality Control (QC) nā papa hana a me nā hiʻohiʻona hāʻawi hana.
Nā Paepae Analytical no nā Immunopeptidomics-Mākaukau Peptides Maʻamau
| ʻĀpana | Papa Noi Hana | Mākaukau Immunopeptidomics | Ke Analytical Validation Method |
|---|---|---|---|
| RP-HPLC Maʻemaʻe | ≥ 90% | ≥ 98% | C18 RP-HPLC (0.1% TFA / ACN gradient, 214 nm) |
| Ka Pono Nui | ± 1.0 A | ≤ 5 ppm (± 0.005 A) | ESI-Orbitrap hoʻonā kiʻekiʻe / MALDI-TOF MS |
| Hoonui Isotopic | > 95% | > 99.0% | ʻO ka nānā ʻana o ka hoʻohelehele ʻana o ka envelopp i Tandem MS |
| Maʻiʻo Peptide Net | ʻAʻole ana ʻia (Kaumaha nui) | Ua hōʻoia ʻia ka waiwai pololei ma o AAA | Ka helu ʻana i ka ʻakika amino nui (AAA) |
| Palapala Hoʻoheheʻe | Nānā wai maka | Hōʻoia i loko 0.1% FA / 1% ACN | Centrifugation & Hōʻoia LC-MS wahi kiʻekiʻe |
| Papa Endotoxin | Kāohi ʻole ʻia | < 0.01 EU/mg | Hōʻike LAL Chromogenic |
| Wahi Hana Hana | Hale Hana Nui | Papa 100 ʻO ka lumi hoʻomaʻemaʻe Ultra-Sterile | ISO 14644-1 Papa 5 nānā kaiapuni |
ʻO ka Turnaround Imperative i ka Neoantigen Screening
I ka maʻi maʻi maʻi immunotherapy a me ka neoantigen hoʻomohala ʻana, Ua hoʻokaʻawale nā mea noiʻi i nā ligand HLA endogenous me ka hoʻohana ʻana i nā pahu e like me ka ʻO Thermo Fisher Pierce MHC Papa I Laʻana Prep Workflow a e ʻike i nā peptides mutated i loko 48 i 72 hola ma o hou kaʻina hana algorithm.
E hōʻoia i nā neoantigens moho, Pono nā mea noiʻi e kauoha koke i ka synthetic heavy-labeled (SIL) hale waihona puke peptide (maʻamau 20 i 96 nā kaʻina) no ka hōʻoia PRM. Kuʻuna peptide alakaʻi manawa o 4 i 6 hana nā pule i kahi bottleneck ʻae ʻole i nā pipeline noiʻi lapaʻau. Pono nā mea kūʻai peptide maʻamau i kēia manawa e hāʻawi i ka synthesis 96-well parallel me kahi 5 i 7 ka huli ʻana o ka lā ʻoihana me ka hoʻolele ʻole i nā paepae QC analytical.
Nā hoʻololi hoʻololi no nā mea hoʻolako peptide maʻamau: Hiki i ka mea noiʻi hoʻokomo
E kōkua i ka poʻe noiʻi e hoʻopaʻa i nā pahu immunopeptidomic maʻamau me ka hilinaʻi piha, Pono nā mea hoʻolako peptide synthesis maʻamau e hoʻololi mai nā mea hana aelike passive i mau hoa bioanalytical kūikawā.
Ke alakaʻi nei i nā paepae synthesis, e like me ʻO ka MOL Changes 'kūikawā peptide synthesis platform, hōʻike i ke ʻano o ka hoʻololi ʻana i ka ʻenehana i hoʻopaʻa ʻia i nā pilikia hoʻohālike i luna.
ʻEkolu mau hoʻoponopono hoʻomaʻamaʻa no nā mea hoʻolako PEPTIDE
- Nā Papa Kūkākūkā i hoʻomākaukau ʻia no nā Immunopeptidomics-mākaukau Allele-Specific Reference Libraries (HLA-A02:01, HLA-A24:02, HLA-B*0:02) Nā Kūlana Hoʻopaʻa Manawa (PRTC-grade isotopically hoʻohuihui ʻia)
- Nā Pane Immunopeptidomics QC Kūlana Kiʻekiʻe-Res ESI-MS Mass Accuracy (<= 5 ppm) & Hoonui Isotopic (> 99.0%) AAA Net Peptide Content Certification & 1% TFA Solubility Hoao
- Lepa Kaumaha SIL wikiwiki & ʻO ka lumi hoʻomaʻemaʻe hoʻomaʻemaʻe kiʻekiʻe-Throughput Parallel 96-Well SPPS (5-7 Puka La) Papa 100 Hana ʻia ka lumi hoʻomaʻemaʻe no ka hoʻopau ʻana i nā mea hoʻohaumia MS Background
1. ʻO nā huaʻōlelo i hoʻomākaukau ʻia no ka Immunopeptidomics
Pono nā mea hoʻolako peptide e hāʻawi i hoʻolālā mua ʻia, ʻO nā hale waihona puke peptide i loiloi mua ʻia i hoʻohālikelike ʻia i nā supertypes nui HLA me ka hui ʻana o ka calibration manawa paʻa..
- Hale Waihona Puke Kuhikuhi Allele: ʻO nā pūʻulu mua i hoʻohui ʻia o nā ligand endogenous kiʻekiʻe no nā alleles kanaka (e.g., HLA-A*02:01, HLA-A*24:02, HLA-B*0:02, a me HLA-DRB1*01:01). He mau mana maikaʻi kēia no ka pono hoʻonui i ka immunoaffinity kit.
- Hoʻopaʻa manawa hoʻohuihui ʻana: ʻO nā cocktails peptide i hoʻopaʻa inoa nui ʻia e pili ana i ka spectrum hydrophobicity holoʻokoʻa (manawa paʻa gradient mai 5% i 65% ACN). Hoʻopili ʻia i loko o nā ʻeluates ma mua o ka hoʻomaʻemaʻe C18, ʻAe kēia mau maʻamau i ka hoʻoponopono ʻana i ka manawa paʻa ma waena o nā holo LC-MS he nui.
2. Nā Pane QC Immunopeptidomics i manaʻo ʻia
Ma mua o ka hāʻawi ʻana i nā palapala hōʻoia maʻamau (CoAs) loaʻa nā ʻōhiʻi ʻike HPLC kumu, Pono nā mea hoʻolako peptide e hoʻokomo i nā panela LC-MS QC kūikawā:
Immunopeptidomics CoA maʻamau: Loaʻa i kēlā me kēia peptide synthesized ka ESI-MS i ke ana nuipaʻa pololei (≤ 5 ppm), tandem MS isotopic enrichment hoʻonui (> 99.0%), AAA-hōʻoiaʻiʻo net peptide kuʻina, a me ka hoʻopaʻapaʻa solubility i 0.1% FA / 1% ACN.
Ma ka leveraging ka isotope kaumaha (SIL) nā kūlana peptide kākoʻo ʻia e ka ʻupena AAA i hōʻoia ʻia, Hoʻopau ka poʻe noiʻi i ka manaʻo koʻikoʻi i ka wā e hoʻokumu ai i nā pihi calibration quantification piha ma nā paepae Orbitrap LC-MS.
3. Hoʻopaʻa inoa ʻana i ke Kaumaha Kaumaha-Isotope & Hoʻohui ʻia ʻo Cleanroom
Pono nā paepae peptide maʻamau e hoʻohui i ka Solid-Phase Peptide Synthesis (SPSS) lako me ka isotope paʻa i kapa ʻia nā amino acids (^{13}C₆, ^{15}N₄-Arg a me ^{13}C₆, ^{15}N₁ Papa inoa).
Eia kekahi, e pale i nā mea haumia kaiapuni mai ke keʻakeʻa ʻana i ka ʻike ligand HLA haʻahaʻa haʻahaʻa, hoʻohuihui, ka hoomaemae ana, a pono e hana ʻia nā aliquoting i loko o kahi ʻenehana hana sterile. Nā lako e hoʻohana ana i ka a Papa 100 kaiapuni lumi maʻemaʻe a me ka mana maikaʻi LC-MS i hōʻoia ʻia e hōʻoia i ka hoʻopau ʻana i ka ion background a me nā pae endotoxin ultra-haʻahaʻa (< 0.01 EU/mg) kūpono no ka ho'ā ʻana o ka cell T-cell i lalo.
Ka papa inoa o ka loiloi loiloi mea kūʻai aku no nā peptides maʻamau kūpono i ka pahu
I ka loiloi ʻana i nā mea hoʻolako peptide maʻamau no nā kūlana kuhikuhi immunopeptidomics a me nā hale waihona puke SIL, Pono nā hui kūʻai bioanalytical e hoʻohana i kēia matrix hoʻoholo:
| Nā Koina Loiloi | Mea Hoʻolako Peptide Kuʻuna | Mea kūʻai i hoʻopili ʻia i ka Immunopeptidomics (MOL Changes) | Pilikia / Ka hopena ma ke Kaʻina Hana Hana |
|---|---|---|---|
| Kaiapuni Synthesis | Pahu hāmama / lab maʻamau | Papa 100 ʻO ka lumi hoʻomaʻemaʻe Ultra-Sterile | Ka leo MS hope loa & ka hoʻohaumia ʻana o ka endotoxin i nā hoʻāʻo cell |
| Hooia Maemae | RP-HPLC wahi kiʻekiʻe (214 nm) | ʻElua RP-HPLC & HR-ESI-MS (≤ 5 ppm) | ʻO nā peptides holoi ʻole i ʻike ʻia ke kumu o ka hoʻopilikia ʻana i nā kahawai PRM |
| Ke kumu helu helu | Ke kaumaha nui Gravimetric | Maʻiʻo Peptide Net i hōʻoia ʻia e AAA | A hiki i 35% kuhi hewa i ka huina AQUA |
| Hoonui Isotopic | > 95% nui SIL | > 99.0% hōʻoia kaumaha hoʻonui | Hoʻokumu ka leaka o ka isotope māmā i nā hōʻailona endogenous |
| Kākoʻo Solubility | Hoʻāʻo wai kumu | ʻO ka hoʻāʻo ʻana i ka pale (0.1% FA / 1% ACN) | ʻO ka ua ʻo Peptide i loko o nā kīʻaha LC autosampler e hōʻemi ana i ka hōʻailona |
| Hoʻololi hoʻouna | 4 i 6 pule pule | 5 i 7 nā lā ʻoihana (96-punawai panels) | Stalls neoantigen validation and clinical sample processing |
Nā Manaʻo Manaʻo no nā mea noiʻi Immunopeptidomics
ʻO ka hoʻomaʻamaʻa ʻana o ka hoʻomākaukau ʻana o ka laʻana o nā hiʻohiʻona hiʻohiʻona ma lalo o nā kits e like me Thermo Fisher's Pierce MHC Kit kahi hana nui i mua no ka noiʻi proteomics.. Eia naʻe, paʻa paʻa ka holomua analytical i ka maikaʻi o nā peptides synthetic upstream.
No ka hoʻonui ʻana i ka sensitivity assay a me ka pololei quantitative:
- Kauoha i ka AAA-Certified Net Content: Mai hilinaʻi ma luna o ke kaumaha o ka pauka lyophilized nui no ka mea kaumaha AQUA peptide spike-ins. E koi i ka palapala AAA e hōʻoia i ka helu molar pololei.
- E hōʻoia i nā paepae hoʻonui isotopic: E hōʻoia i ka lawe ʻana i nā peptides kaumaha > 99.0% ka maʻemaʻe isotopic e pale aku i ka hoʻopaʻa ʻana o ka hōʻailona kaulahao māmā ma nā spectrometers Orbitrap nui-kiʻekiʻe..
- Hui pū me nā Mea Hoʻolako Synthesis Kūikawā: E hana pū me nā mea hoʻolako peptide hiki ke hana i nā kaʻina hana maʻamau i loko o ka Papa 100 nā lumi lumi maʻemaʻe a me ka hoʻopuka wikiwiki, nā hale waihona puke peptide SIL.
Ma ka hoʻohālikelike ʻana i nā kikoʻī peptide maʻamau i luna me nā pahu hoʻomākaukau hoʻohālike i lalo, hiki i nā mea noiʻi ke hana i nā haʻawina immunopeptidomics me ka hilinaʻi nui.
No nā mea noiʻi e ʻimi nei i nā hale waihona puke peptide maʻamau, nā kūlana i hoʻopaʻa ʻia i ka isotope kaumaha, a i ʻole nā panela immunopeptidomics QC, e kūkākūkā me nā loea bioanalytical ma MOL Changes e kūkākūkā e pili ana i ke kaʻina hana maʻamau a me nā koho synthesis lumi maʻemaʻe.
Mea kākau & Nānā ʻenehana
Nānā ʻia e ka MOL Changes Bioanalytical R&Hui D
Kiekie Mass Spectrometry & Nā Kauka Hana Hana Peptide
Ua kākau ʻia a loiloi ʻia kēia loiloi e bioanalytical R&D loea ma MOL Changes, ka hoʻohui pū ʻana i ka ʻike i ka mass spectrometry-grade custom peptide synthesis, hōʻailona isotope paʻa, a me ka hana lumi maʻemaʻe no ka noiʻi immunopeptidomics pololei.
